You are here

eye disease

AbbVie and Capsida Biotherapeutics partner on eye disease focused gene therapies

AbbVie and Capsida Biotherapeutics partner on eye disease focused gene therapies

Biopharma Reporter

Capsida Biotherapeutics

drug development

Flag link:

AbbVie, Capsida Set Sights on Gene Therapies for Eye Diseases

AbbVie, Capsida Set Sights on Gene Therapies for Eye Diseases

BioSpace

Capsida Biotherapeutics

Flag link:

Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail

Merck & Co. bails on NGM eye disease collab in wake of phase 2 fail

Fierce Biotech

NGM Biopharmaceuticals

clinical trials

geographic atrophy

Flag link:

Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment

Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment

Investors Business Daily

Apellis Pharmaceuticals

geographic atrophy

Flag link:

Hovione's drug delivery tech lands eye disease licensing deal

Hovione's drug delivery tech lands eye disease licensing deal

Fierce Pharma

Ji Xing Pharmaceuticals

Flag link:

Another Oxurion eye disease drug flunks phase 2, leaving biotech all-in on last prospect

Another Oxurion eye disease drug flunks phase 2, leaving biotech all-in on last prospect

Fierce Biotech

Flag link:

Intellia looks to eye diseases in latest deal

Intellia looks to eye diseases in latest deal

BioPharma Dive

Intellia Therapeutics

Flag link:

Can a topical treatment beat blockbuster eye injectables? A Swiss biotech has the cash now to find out

Can a topical treatment beat blockbuster eye injectables? A Swiss biotech has the cash now to find out

Endpoints

Flag link:

Unity Bio Restructuring Cuts 30% of Staff, Keeps Focus on Eye Drug

Unity Bio Restructuring Cuts 30% of Staff, Keeps Focus on Eye Drug

Xconomy

Unity Biotechnology

Flag link:

Biogen boosts gene therapy strategy with Harvard pact focused on inherited eye disease

Biogen boosts gene therapy strategy with Harvard pact focused on inherited eye disease

Fierce Biotech

Flag link:

AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis

Xconomy

AsclepiX Therapeutics

wet age-related macular degeneration

retinal occulsion

Flag link:

Novartis Considers Offer for Takeda Eye-Disease Assets

Novartis Considers Offer for Takeda Eye-Disease Assets

Bloomberg

Flag link:

How this biotech plans to go up against big pharma with its eye disease products

How this biotech plans to go up against big pharma with its eye disease products

Drug Delivery Business News

Flag link:

Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases

Regeneron and Bayer To Jointly Develop Novel Combination Therapy for Eye Diseases

Yahoo

Flag link:

Biogen enters eye-treatment arena with AGTC deal

Biogen enters eye-treatment arena with AGTC deal

Yahoo/Reuters

Flag link:

Bayer bets on Johns Hopkins for eye disease R&D

Bayer bets on Johns Hopkins for eye disease R&D

Fierce Biotech

Flag link:

Two Promising Gene Therapy Stocks Tackling Eye Disease

Two Promising Gene Therapy Stocks Tackling Eye Disease

TheStreet.com

Applied Genetic Technologies

Avalanche Biotechnologies

Flag link:

IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery

IRIDEX Granted U.S. Patent for Adjustable Laser Probe for Eye Surgery

Flag link:

Otsuka Pharma extends research collaboration with MethylGene

Otsuka Pharma extends research collaboration with MethylGene

Pharmabiz

Flag link:

Alcon Boosts Presence In Eye Disease Market

Alcon Boosts Presence In Eye Disease Market

Yahoo/Investors Business Daily

Flag link: